Key result
Renin-based treatment modification in patients with resistant hypertension reduced mean systolic blood pressure from 163 mm Hg to 140 mm Hg.
Why the study?
Does renin-based treatment modification improve blood pressure control in patients with resistant hypertension?
Cohort (n=73)
No
Does renin-based treatment modification improve blood pressure control in patients with resistant hypertension?
Answers are grounded in this paper and cite their sources.
Tailoring antihypertensive therapy based on plasma renin activity profiling can significantly improve blood pressure control while reducing the number and cost of medications in patients with resistant hypertension.
Hypertension afflicts 43 million people in the U.S. and is a leading risk factor for cardiovascular morbidity and mortality.1 Accordingly, blood pressure measurement is one of the most common reasons for a visit to the doctor's office. Nevertheless, there is considerable evidence that the current strategies used to diagnose and treat hypertension are inadequate. The recent National Health and Nutrition Examination Survey (NHANES III) reported that fewer than half of treated hypertensives are controlled and fewer than 30% of all hypertensives in the U.S. have their blood pressure <140/90 mm Hg.2 Furthermore, recent evidence indicates that the treatment guidelines established by the Fifth Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure (JNC V) have not been accepted by practicing physicians.1,3 This problem is not limited to the U.S., as evidenced by the recent report by Poggi et al that blood pressure control is adequate in only about 10% of hypertensives in France.4 Reasons for failure to attain adequate blood pressure control are manifold. A central factor is the widely held misconception that hypertension is a single disease that can be treated by one recipe. As a consequence of this reasoning, both the physician and patient are caught in a crossfire of guidelines of “preferred” treatment approved by the federal government and of marketing claims by the pharmaceutical industry that their single product fits all patients equally.5 In reality, hypertension is a heterogeneous disorder that can be characterized by: (i) pathophysiologic mechanisms that can be defined by disease-specific hormonal and biochemical parameters; (ii) individual variations in response to specifically targeted antihypertensive medication, thus defining different vasoconstrictor mechanisms in individual patients; and (iii) highly variable levels of risk for premature death and morbid events, which cannot be predicted solely by the blood pressure level.6 A more rational approach to the diagnosis and treatment of the individual hypertensive patient can be developed by exploring our ability to identify and quantify derangements in the fundamental processes that govern normal blood pressure.7 Ideally this goal should be accomplished in those patients who are at increased risk of target organ injury. Accordingly, the cybernetic relationship between renin-angiotensin and sodium normally regulates blood pressure and body volume.8 In hypertensive patients, the reciprocal relationship between plasma renin activity (PRA) and sodium intake is qualitatively similar, but there is a much broader distribution of renin levels.6,8 PRA is low in about 30% of patients, indicating an appropriate renal baroreceptor response to high pressure (low-renin hypertension). By contrast, in about 15% of patients, PRA is frankly elevated (high-renin hypertension), and in about half it is in the medium range and is indistinguishable from normotensives (medium-renin hypertension). Thus, in about 70% of all hypertensives, renin secretion is inappropriately high for the blood pressure level and either solely provides, or contributes importantly to, the mechanism for increased vasoconstriction and hypertension. Accordingly, stratification of individual hypertensives according to these derangements in renin secretion provides a solid basis for identifying curable causes of hypertension at the outset, selecting effective antihypertensive medication, and assessing cardiovascular risk.6,7 The height of the blood pressure, by itself, does not provide sufficient information to accomplish these goals. For example, blood pressure levels are comparably elevated in two curable forms of hypertension, unilateral renovascular hypertension and primary aldosteronism. However, the PRA level is suppressed in primary aldosteronism (< 0.64 ng/mL/h) and stimulated in renovascular hypertension (> 3.0 ng/mL/h).8,9 Therefore, these disorders are clearly distinguishable by the accompanying PRA, but not by the blood pressure or other clinical and laboratory features. Furthermore, the failure to appropriately suppress renin secretion in patients with essential hypertension has been associated with an increased risk of myocardial infarction.6 The benefits of measuring the PRA level are not limited to identification of curable forms of hypertension and assessment of cardiovascular risk. In essential hypertension, the PRA level is a marker for the primary pressor mechanism and, therefore, can often guide the selection of effective antihypertensive medication and enable monotherapy for most patients.7 In those with renin-dependent vasoconstriction, blood pressure can be lowered most effectively by antirenin and antiangiotensin therapies (eg, ACE inhibitors, β-blockers, Type 1 angiotensin II receptor blockers). By contrast, when PRA activity is low, blood pressure reduction is accomplished more effectively by sodium-volume reduction (eg, dietary sodium restriction, diuretics), α1-adrenergic receptor blockers, and calcium channel blockers. The benefits of measuring the PRA level for guiding drug selection are not limited to the previously untreated patient, but also encompass the patient who is refractory to antihypertensive treatment. For example, the reactive rise in renin-angiotensin-aldosterone during diuretic therapy attenuates the natriuretic and antihypertensive effects of thiazide-type diuretics. This accounts for the complementary effects of antirenin therapy in patients resistant to diuretic monotherapy.7 These salutary effects of PRA measurement were further reinforced by an analysis of 73 outpatients (39 men, 34 women) with hypertension resistant to treatment with one or more agents (systolic > 140, diastolic > 90) who were referred recently to the Hypertension Center at The New York Hospital-Cornell Medical Center (Table 1; Figure 1). At the initial visit, patients were being treated with 2.1 ± 0.1 antihypertensive medications. While on the medication regimen at the time of referral, their mean systolic pressure was 163 ± 3 mm Hg (> 170 mm Hg in 42%) and diastolic pressure 95 ± 1 mm Hg (> 100 mm Hg in 36%). The mean PRA at entry, obtained during treatment, was 5.0 ± 1.2 ng/mL/h). Blood Pressure and Drug Costs Fall During Renin-Based Treatment Blood Pressure and Drug Costs Fall During Renin-Based Treatment Patients were subsequently assessed using a renin-based analysis and treatment modified according to the principles described above. During a 1-year follow-up period, blood pressure improved when compared with the initial visit: systolic 140 ± 2 mm Hg (P < .0001; < 140 mm Hg in 60%) and diastolic 84 ± 1 mm Hg (P < .0001; < 90 mm Hg in 86%). Furthermore, the mean number of medications decreased to 1.5 ± 0.1 per patient (P < .0001; ≤ 2 drugs in 92%). Of note, there was a 20% reduction in total cost of medication per patient. In addition, secondary etiologies of hypertension were newly detected in 17.8% of this study population, with renovascular hypertension and primary aldosteronism each accounting for about half of those diagnoses. The results of this study support the larger body of data that reinforces the concept that antihypertensive treatment based on PRA measurement improves the accuracy of selecting antihypertensive medications, facilitates detection of secondary hypertension, and increases the efficacy of treating patients with resistant hypertension. In summary, the current strategies for antihypertensive therapy are inadequate and reflect the older view that hypertension is a homogenous disorder that can be treated with a single therapeutic recipe. Treatment efficacy can be improved by an analysis of the volume vasoconstriction mechanisms based on plasma renin profiling and has been confirmed by sequential use of single antihypertensive agents that have specific pharmacologic targets.
No takes yet. Share an insight, caveat, or question.
Blumenfeld et al. (1998) conducted a cohort in Resistant hypertension (n=73). Renin-based analysis and treatment modification vs. Baseline (prior to treatment modification) was evaluated on Systolic blood pressure (mm Hg) (p=<.0001). Renin-based treatment modification in patients with resistant hypertension reduced mean systolic blood pressure from 163 mm Hg to 140 mm Hg.
Synapse has enriched 10 related papers. Consider them for comparative context: